A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)
A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.
Entry Criteria:
Inclusion Criteria:
Exclusion Criteria:
Sandeigo, California 92103, United States
Lake Charles, Louisiana 70601, United States
Calle 80#47-43 Consultorio 5C, Barranquila S/N, Colombia
Calle 103A # 21-49, Bogota S/N, Colombia
Str. Octavian Goga Nr. 17, Arad 310022, Romania
Sos. Berceni Nr. 10-12, Bucharest 041914, Romania
Kyviv, Ukraine